This paper summarized TONG Xiaolin's clinical experience in using "poisonous" Chinese material medica to treat metabolic diseases， who believes that toxicity reducing and efficacy enhancing can be achieved through carefully considered dosage， reasonable combination of medicinals， and appropriate preparation and administration ways.By analyzing the functions of Chinese material medica and findings from modern pharmacology and toxicology， the clinical dosage features， combination of medicinals and medication， preparation and administration methods and other precautions have been summarized regarding Huanglian （Rhizoma Coptidis） in treating diabetes， Xixin （Radix et Rhizoma Asari）， Dahuang （Radix et Rhizoma Rhei） and Shuizhi （Hirudo） in treating diabetic kidney diseases， Zhichuanwu （Radix Aconiti Praeparata）， Zhicaowu （Radix Aconiti Kusnezoffii Praeparata）， Xixin and Zhimaqianzi （Semen Strychni Praeparata） in treating diabetic peripheral neuropathy， Yinyanghuo （Herba Epimedii） and Wugong （Scolopendra） in treating diabetic erectile dysfunction， Fuzi （Radix Aconiti Lateralis Praeparata） and Banxia （Rhizoma Pinelliae） in treating diabetic gastroparesis， Hongqu （Monascus purpureus Went） and Weilingxian （Radix et Rhizoma Clematidis） in treating metabolic syndrome， as well as Leigongteng （Radix Tripterygii Wilfordii） and Huangyaozi （Rhizoma Dioscoreae Bulbiferae） in treating Hyperthyroidism， thereby providing reference for precise clinical medication.

[Abstract] In the past, surgery and chemotherapy were the main treatment strategies for malignant melanoma, but companied with poor prognosis. With the development of high-throughput gene sequencing technology and the deepening understanding of tumor molecular mechanisms, it has been found that tumor heterogeneity and the diversity of tumor microenvironment affect tumor formation, drug resistance and treatment selection, leading to different responses and benefits of melanoma patients to the same treatment. The emerge and progression of targeted therapy and immunotherapy have significantly increased the survival rates of patients with metastatic melanoma, promoting the individualization and precision of melanoma treatment and making precise treatment a research hotspot as well as a trend. This review mainly summarizes the research progress of systemic individualized treatment of advanced melanoma based on precise subtyping and molecular level, and to get a more comprehensive view of the survival status of melanoma patients in the era of precision medicine, as well as the prospect and necessity of developing various targeted therapy, immunotherapy or combination therapy.